Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222917 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
A Phase 2 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT07222917: Recruiting Phase 2 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.
NCT07222917 is a Phase 2 study of Chronic Kidney Disease and Hypertension that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222917, a Phase 2 study of Chronic Kidney Disease and Hypertension, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Primary Outcome
Change from baseline in UACR
Conditions Studied
Interventions
- DRUG Baxdrostat/dapagliflozin
- DRUG Baxdrostat/Placebo
Study Locations (20)
Florida
- Research Site - Hollywood
- Research Site - Port Charlotte
- Research Site - Port Orange
North Carolina
- Research Site - Greenville
- Research Site - Jacksonville
- Research Site - New Bern
Texas
- Research Site - Arlington
- Research Site - Pasadena
- Research Site - San Antonio
Other
- Research Site - Buenos Aires
- Research Site - Ciudad de Buenos Aires
Arizona
- Research Site - Surprise
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Champaign
Kansas
- Research Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2027-05-24 |
| Phase | Phase 2 |
What NCT07222917 shows while recruiting
NCT07222917 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).
The record links to 1 condition, with Chronic Kidney Disease and Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Baxdrostat/dapagliflozin is the first listed.
NCT07222917 names 20 study sites across 13 states, led by Florida, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07222917 about?
NCT07222917 is a clinical study titled "A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.". International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
What is the current status of trial NCT07222917?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2025-12-05. Estimated completion is 2027-05-24.
What conditions does trial NCT07222917 study?
This clinical trial studies the following conditions: Chronic Kidney Disease and Hypertension.
What interventions are being tested in trial NCT07222917?
The interventions under investigation include: Baxdrostat/dapagliflozin (DRUG), Baxdrostat/Placebo (DRUG).
Who is sponsoring clinical trial NCT07222917?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222917 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease and Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222917's enrollment target sits among peer trials
218 284th of 2000 higher than 1,716 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RECRUITING · Phase 3
-
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI